Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double Blind Study of CS-3150 to Evaluate Efficacy and Safety Compared to Placebo in Japanese Type 2 Diabetic Patients with Microalbuminuria (ESAX-DN study)

Next Previous
Trial Profile

A Double Blind Study of CS-3150 to Evaluate Efficacy and Safety Compared to Placebo in Japanese Type 2 Diabetic Patients with Microalbuminuria (ESAX-DN study)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 23 Mar 2018

At a glance

  • Drugs Esaxerenone (Primary)
  • Indications Diabetic nephropathies
  • Focus Registrational; Therapeutic Use
  • Acronyms ESAX-DN study
  • Sponsors Daiichi Sankyo Company

    • Most Recent Events

    • 20 Mar 2018 Status changed from recruiting to active, no longer recruiting.
    • 22 Sep 2017 Status changed from not yet recruiting to recruiting.
    • 08 Sep 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top